The genital herpes market is expected to grow significantly owing to the increase in diagnosed genital herpes cases per year, awareness, and anticipated launch of emerging therapies by key players
/PRNewswire/ DelveInsight s Genital Herpes Market Insights report includes a comprehensive understanding of current treatment practices, genital herpes.
As per DelveInsight analysis in the Chlamydia Market Report, the disease awareness and emergence of new products in the pipeline will add to the Chlamydia market growth in the future. In addition
/PRNewswire/ DelveInsight s Chlamydia Market Insights report includes a comprehensive understanding of current treatment practices, Chlamydia emerging.
25+ active players in the domain working on 25+ pipeline therapies.
Key Genital Herpes pipeline therapies such as
HSV 2 Vaccines, RVx-201, NE HSV-2 Vaccine, HDIT 101, Pritelivir, UB-621, and others are under investigation in different phases of clinical trials for the treatment of Genital Herpes.
Sanofi, Rational Vaccines, BlueWillow Biologics, Heidelberg, ImmunoTherapeutics, AiCuris, United Biopharma, among several others, are some of the key prominent pharma players working in the domain.
In
May 2021, X-Vax Technology announced that it is preparing to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its experimental vaccine against herpes simplex virus 1 and 2 (HSV-1 and -2).